{
    "clinical_study": {
        "@rank": "99001", 
        "arm_group": [
            {
                "arm_group_label": "Testosterone undecanoate", 
                "arm_group_type": "Experimental", 
                "description": "testosterone undecanoate 40 mg orally  twice a week plus progynova 1mg oral daily"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo twice a week with progynova 1 mg oral daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Additional testosterone undecanoate can improve female sexual function in postmenopausal\n      women which one aspects of quality of life. The dose adjustment can reduce incidence of\n      adverse effects and low cost of treatment with effective outcome."
        }, 
        "brief_title": "Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Female Sexual Dysfunction", 
        "condition_browse": {
            "mesh_term": "Sexual Dysfunctions, Psychological"
        }, 
        "detailed_description": {
            "textblock": "Research Question:\n\n      \" Does oral testosterone undecanoate improve sexual problem in postmenopausal women? \" Type\n      Research:Clinical research\n\n      Study design:\n\n      Randomized double-blinded placebo controlled trial"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  postmenopausal  women with age between 40-60 years\n\n          -  Women complain about her sexual problem and her score of Female Sexual Function Index\n             \u2264 26.5\n\n        Exclusion Criteria:\n\n          -  women with previous use of hormonal replacement or anti-psychiatric drugs within 3\n             months\n\n          -  women with history of or present premalignancies/malignancies\n\n          -  women present with liver disease or abnormal liver enzyme\n\n          -  women with active cardiovascular, cerebrovascular or thromboembolic disorders\n\n          -  women with Present psychiatric disease\n\n          -  Partner have sexual dysfunction"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724658", 
            "org_study_id": "CU0115"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testosterone undecanoate", 
                "description": "testosterone undecanoate 40 mg orally twice a week", 
                "intervention_name": "Testosterone undecanoate", 
                "intervention_type": "Drug", 
                "other_name": "Andriol"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo orally twice a week with progynova 1 mg oral daily", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "female sexual function", 
            "postmenopause", 
            "testosterone"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bankok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "King Chulalongkorn memorial hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women", 
        "overall_official": {
            "affiliation": "Menopause unit of Chulalongkorn hospital", 
            "last_name": "Reuthairat Tungmunsakulchai, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "female sexual function index score", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724658"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "12626215", 
            "citation": "Fl\u00f6ter A, Nathorst-B\u00f6\u00f6s J, Carlstr\u00f6m K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric. 2002 Dec;5(4):357-65."
        }, 
        "secondary_outcome": {
            "description": "weight gain\nacne\nhirsutism.\nvaginal bleeding", 
            "measure": "adverse effects of the drug", 
            "safety_issue": "Yes", 
            "time_frame": "8 week"
        }, 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}